Antibiotic-associated encephalopathy: A retrospective pharmacovigilance study based on 21 years of data from the US FDA Adverse Event Reporting System. [PDF]
Wang H +4 more
europepmc +1 more source
Factors associated with completion of 6 months of isoniazid preventive therapy among under-five children exposed to tuberculosis patients in Blantyre, Malawi. [PDF]
Mzama GT +4 more
europepmc +1 more source
Correction: Germ-line exon 21 EGFR V831H mutation in advanced NSCLC resistance to almonertinib: a case report. [PDF]
Cai D, Lou J, Zhu Y, Wang Y.
europepmc +1 more source
Real-World Assessment of the Xpert MTB/XDR for Detecting Isoniazid and Second-Line Drug Resistance Among TB Patients. [PDF]
Makhon A +6 more
europepmc +1 more source
COVID-19 as a Potential Trigger for Tuberculosis: Insights From a Large-Scale Japanese Insurance Database Analysis. [PDF]
Miyamori D, Ikeda K, Nagasaka S, Ito M.
europepmc +1 more source
Efficacy, safety, and completion of modified short-course rifapentine and isoniazid for latent tuberculosis infection in patients with high-risk rheumatic disease: a multicentre, open-label, randomized, non-inferiority trial. [PDF]
Zhang L +29 more
europepmc +1 more source
Cumulative effect of cotrimoxazole, isoniazid and opportunistic infection prophylaxis on CD4 response among people living with HIV on first-line ART in Ari Zone, Southern Ethiopia. [PDF]
Ahmed S, Tento T, Ahmed N.
europepmc +1 more source
Drug-Resistant Tuberculous Spondylitis Treated with Bedaquiline-Containing Regimens in South Korea: Two Case Reports. [PDF]
Lee KY, Hyun M, Lee JY, Kim HA.
europepmc +1 more source
Current and emerging therapies for pulmonary tuberculosis in adults. [PDF]
Mahmood A +5 more
europepmc +1 more source

